Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. - Wikidata - wikimedia - TriplyDB

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

http://www.wikidata.org/entity/Q37252144

about

Recent progress in pancreatic cancer Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians Imaging preoperatively for pancreatic adenocarcinoma New challenges in perioperative management of pancreatic cancer Radical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a Case A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review.Percutaneous ultrasound-guided core needle biopsy of solid pancreatic masses: Results in 250 patients.Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.Comparison of preoperative imaging and pathological findings for pancreatic head adenocarcinoma: A retrospective analysis by the Association Française de Chirurgie.First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.Pancreatic cancer-improved care achievable Post-brushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: The Papanicolaou Society of Cytopathology Guidelines S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer Does the use of neoadjuvant therapy for pancreatic adenocarcinoma increase postoperative morbidity and mortality rates?A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines.The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma.A prospective, randomized trial of pancreatectomy combined with isolated hepatic perfusion via a dual route or conventional postoperative adjuvant therapy in patients with advanced pancreatic head carcinoma.Quality appraisal of clinical practice guidelines on pancreatic cancer: a PRISMA-compliant article.Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling.The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment.Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic Management Multimodality treatment of recurrent pancreatic cancer: Mith or reality?Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer Response evaluation following neoadjuvant treatment of pancreatic cancer patients Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results Comparison of Multidetector CT and Gadobutrol-Enhanced MR Imaging for Evaluation of Small, Solid Pancreatic Lesions.Current status of chemotherapy for the treatment of advanced biliary tract cancer.Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.Pancreatic ductal adenocarcinoma staging.Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development.

P2860

Q24626346-4DF2B212-80F9-467C-8A67-3B7791130DF3 Q26767041-E29B78DE-0DF2-4FAD-837B-B1B9663910A5 Q26799450-EB0711C5-7227-46A9-B0C4-A271BFD071F8 Q28082422-F94C4909-B6DB-4994-BE9C-6EFEDB5CDDE1 Q28388329-92076984-B172-4B6E-96B1-2D9557A0385B Q30238706-6BA52B71-83E4-4B5F-9AE7-8128D766A110 Q33167097-151EC893-08C3-4B5F-8CF2-C00A30708953 Q33558951-9DF39C83-4C15-4A96-A7EF-C3D22FFAA9D7 Q33818221-4902DA56-67D6-4042-9AA0-7A7153DFA2B2 Q34008520-9F253F98-45CB-48F0-968E-A1C822FD4AE7 Q34036659-17D5F331-54CC-40B6-8154-5DCF427C2638 Q34127306-1A33B59E-88F0-4B20-8E18-DF24DDBED516 Q34326711-B6A6DA05-BC9F-40EF-A3F6-E11372001C7E Q34539541-31080627-CBD0-4ED2-8451-2BD3BCF019A4 Q34892858-60274C05-ACDD-44A1-9106-299017B17033 Q34941883-FBEDEF96-6418-48C3-992A-DDFED34AD78D Q35028999-1AFB46A4-7234-4297-8B6F-544F362358FB Q35118758-6C33D6EA-5F32-47BC-B6C9-3383B197C339 Q35147520-F3725133-44A5-4403-956F-593ADF4870CD Q35155573-5B97B157-89EE-45D2-AF3D-E7974A793AB3 Q35202400-2DF65FE7-3701-4AD3-BDAA-ADE732A343D1 Q35213015-4420AAF9-1200-42EA-9E9E-BF64D018074A Q35339214-F6A0BEF4-962A-4F81-951D-637BD6E15917 Q35679643-EBF875B9-659F-41E4-A035-AB9DCDCFDD36 Q35791513-88BCBE8D-5C97-4CA2-AC50-0B571447AD09 Q36009104-89AEE657-984A-48FE-A28F-F1D725517D59 Q36099266-E00D0ECD-178A-4340-A4C4-ED94BAC4EB33 Q36194657-624829CB-A81E-4930-AC33-D4BFCB8C679E Q36195812-D9A43C91-32FD-49D6-8828-4ED4DAC08EB4 Q36281575-44EBE9A5-4279-4E83-865C-0B6BE0B27DB2 Q36369834-AC35299F-275C-46F8-873C-8DACC499638B Q36540475-DB8AAAFF-5656-4F19-9F80-A4AF6941B06B Q36693226-99DD28B6-EB50-4907-A25F-B19826BF6B97 Q36764997-859AD65A-7B65-403C-BBA7-521E71D93825 Q37073536-A5FB0887-9DDB-42CA-83EC-E7F247E616B3 Q37138732-55DA089E-39EC-4232-B144-0051770FAA4E Q37151112-AD463296-56DF-4093-A808-A5064ED83199 Q37193819-2537DDD8-7541-43F7-AE6A-A3A3F3A3B64B Q37357401-6F5CFEC1-DDEB-4FB8-B082-F55FCEECD4E9 Q37413146-A71FFFA5-13F9-40BC-AC7D-49C61F377D7A

P2860

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

http://www.wikidata.org/entity/Q37252144

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

@en

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

@nl

type

label

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

@en

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

@nl

prefLabel

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

@en

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.

@nl

P1433

Q37252144-8228D92E-8522-4898-8AD1-223BE612E5F6

P1476

Q37252144-92C28EF1-7AEC-4713-A13A-649E5C22C106

P2093

Q37252144-0DD1924E-21B5-4081-846C-EE7A3269657E

Q37252144-23D57F48-4C84-4093-AC20-054A6773124A

Q37252144-2980D5FB-C7B7-46DF-956F-9F01E58F5E0C

Q37252144-31FBDC9A-F0F6-4F3A-8C3F-B0428F099F03

Q37252144-4B3D2902-07CC-487F-8ED2-41F49F6C2805

Q37252144-53A86FA9-84C4-4FD8-B666-2F47EDCDFB7C

Q37252144-53BE5C9A-426A-40A3-A3C4-D829775AEBD0

Q37252144-6375BCF2-60A8-430F-A770-7A3D52BFFCF8

Q37252144-77D4F5A0-B436-4109-93E4-85664D81E26D

Q37252144-782B5B96-C390-4AA0-BFC7-DE97F4160C84

P2860

Q37252144-0F6F450B-6300-4746-BDA7-92DA2DD3EB9E

Q37252144-0FCD6BDF-18AF-41E5-86FE-E657B37AEB47

Q37252144-134DBA9F-C476-4099-9B3D-07E00B36A32B

Q37252144-1C10743F-3740-40AB-956C-D396A9283E4F

Q37252144-26F0F9BA-8544-483A-A039-B6621554DA33

Q37252144-2854DF20-A5A2-4F1D-B57C-64205D1BCB0B

Q37252144-302CF3F1-8A68-45EF-8E38-DAB4A07F1DC7

Q37252144-316AA07A-3A44-4FDD-81FC-21750D7D360C

Q37252144-3E6702F3-7EE7-4181-AF52-F8F3FAAB588D

Q37252144-4102759B-8843-4847-BF73-D90E2C8ED201

P304

Q37252144-62971268-1438-4EA3-8A7D-33D197DFD7A8

P31

Q37252144-FF5C4AFD-0239-4A56-8F36-B5F9311BB089

P356

Q37252144-0CC8CB27-0999-4784-A57F-513B434E8871

P433

Q37252144-1A4CF917-5F87-4E81-9A13-87AEE578DB5E

P478

Q37252144-3C0DEE6D-B8CD-4D06-AE24-D6A500C49171

P50

Q37252144-19634D3A-D5EE-4CA5-8828-EF746076E334

Q37252144-29E171A7-F8E8-49BC-9B35-AEF3958E58C8

Q37252144-D6785D0F-B605-478E-BF0E-BDF7F1068346

P577

Q37252144-528A2441-828A-4F0F-B22C-DC16B9F64400

P698

Q37252144-FB885712-8779-47C1-A985-C49DA101931E

P921

Q37252144-F4004C99-BA81-456D-9C9B-94B2AAE57275

P932

Q37252144-907168B1-1A47-4560-8CFD-C6A23FFA585B

P356

JNCCN.2012.0073

P1433

Journal of the National Comprehensive Cancer Network

P1476

Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines

@en

P2093

Aaron R Sasson

http://www.w3.org/2001/XMLSchema#string

Al B Benson

http://www.w3.org/2001/XMLSchema#string

Andrew Ko

http://www.w3.org/2001/XMLSchema#string

Anitra Tally

http://www.w3.org/2001/XMLSchema#string

Brian Czito

http://www.w3.org/2001/XMLSchema#string

Brian M Wolpin

http://www.w3.org/2001/XMLSchema#string

Deborah A Freedman-Cass

http://www.w3.org/2001/XMLSchema#string

Dorothy A Shead

http://www.w3.org/2001/XMLSchema#string

Edgar Ben-Josef

http://www.w3.org/2001/XMLSchema#string

Ephraim S Casper

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

Cancer statistics, 2012

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Pancreas-protocol imaging at a high-volume center leads to improved preoperative staging of pancreatic ductal adenocarcinoma.

Division of the right posterior attachments of the head of the pancreas with a linear stapler during pancreaticoduodenectomy: vascular and oncological considerations based on an anatomical cadaver-based study.

Predicting resectability of periampullary cancer with three-dimensional computed tomography.

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.

Staging of pancreatic adenocarcinoma by imaging studies.

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.

P304

703-713

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6004/JNCCN.2012.0073

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Peter Muscarella

Srinadh Komanduri

Albert C. Koong

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22679115

http://www.w3.org/2001/XMLSchema#string

P921

P932

3807091

http://www.w3.org/2001/XMLSchema#string